Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function by L. Pastorelli et al.
Research Article
Procoagulatory State in Inflammatory Bowel Diseases
Is Promoted by Impaired Intestinal Barrier Function
Luca Pastorelli,1,2 Elena Dozio,2 Laura Francesca Pisani,2 Massimo Boscolo-Anzoletti,3
Elena Vianello,2 Nadia Munizio,1 Luisa Spina,1 Gian Eugenio Tontini,1 Flora Peyvandi,3,4
Massimiliano Marco Corsi Romanelli,2,5 and Maurizio Vecchi1,2
1Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy
2Department of Biomedical Sciences for Health, University of Milan, 20131 Milan, Italy
3Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
4Department of Medical and Surgical Pathophysiology and Transplantations, University of Milan, 20122 Milan, Italy
5Operative Unit of Laboratory Medicine, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy
Correspondence should be addressed to Luca Pastorelli; luca.pastorelli@me.com
Received 29 October 2014; Revised 27 January 2015; Accepted 1 February 2015
Academic Editor: Gerassimos Mantzaris
Copyright © 2015 Luca Pastorelli et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Inflammatory and immune mediated disorders are risk factors for arterial and venous thromboembolism. Inflammatory bowel
diseases (IBD) confer an even greater risk of thromboembolic events than other inflammatory conditions. It has been shown that
IBD patients display defective intestinal barrier functions. Thus, pathogen-associated molecular patterns (PAMPs) coming from
the intestinal bacterial burden might reach systemic circulation and activate innate immunity receptors on endothelial cells and
platelets, promoting a procoagulative state. Aim of the study was to test this hypothesis, correlating the presence of circulating
PAMPs with the activation of innate immune system and the activation of the coagulatory cascade in IBD patients. Specifically,
we studied lipopolysaccharide (LPS), Toll-like receptor (TLR) 2, TLR4, and markers of activated coagulation (i.e., D-Dimer and
prothrombin fragment F1+2) in the serum and plasma of IBD patients.We found that LPS levels are increased in IBD and correlate
with TLR4 concentrations; although a mild correlation between LPS and CRP levels was detected, clinical disease activity does not
appear to influence circulating LPS. Instead, serum LPS correlates with both D-Dimer and F1 + 2 measurements. Taken together,
our data support the role of an impairment of intestinal barrier in triggering the activation of the coagulatory cascade in IBD.
1. Introduction
Cardiovascular events, including both arterial and venous
thromboembolism, are a major cause of death and morbidity
in Western countries [1]. Several cofactors influence the risk
of cardiovascular events and, among these, inflammation
seems to play a relevant role [2]. In fact, systemic and local-
ized inflammatory processes can accelerate atherosclerosis
and cause a hypercoagulative state [3]. As a matter of fact, the
atherosclerotic plaque is ultimately an inflammatory lesion
[4] where activated macrophages sustain the damage [5]
and the inflammatory and coagulative molecular cascades
are strictly linked and share several common mediators [3].
As such, it is not surprising that a wealth of epidemiologic
data demonstrates an increased prevalence of thromboem-
bolic complications in inflammatory and immune-mediated
disorders [6]. Remarkably, it has been shown that, among
many inflammatory and/or immune-mediated conditions,
inflammatory bowel diseases (IBD), namely, ulcerative colitis
(UC) and Crohn’s disease (CD), confer the most prominent
risk of thromboembolism [7].
IBD are chronic and relapsing inflammatory diseases of
the gut and their exact etiology is still obscure [8]; however,
several key events in the pathogenesis of IBD are well
recognized and studied. It is commonly accepted that the
onset of IBD is linked to the presence of an altered intestinal
permeability [9], a reduced mucosal innate immunity func-
tion [9], and an exaggerated adaptive immune response [10].
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The increased incidence of thromboembolic events in
IBD patients is likely to be multifactorial and the inflam-
matory process may have itself a role together with vitamin
deficiencies (i.e., vitamin B12, vitamin B6, and folate) and
other acquired factors [11–13].Moreover, a defective intestinal
mucosa barrier function may as well contribute to the
procoagulative state, specifically in IBD patients. In fact,
a leaky epithelial layer and/or a defective innate immune
response impair gut capability to control intestinal bacterial
burden, allowing bacterial components to penetrate into
the intestinal mucosa [9], reach the systemic circulation,
and come into contact with endothelial cells and platelets.
Those bacterial components, such as lipopolysaccharide
(LPS), may work as pathogen-associated molecular patterns
(PAMPs), that is, molecules associated with different groups
of microorganisms, and after being recognized by cells they
activate a prompt innate immune response [14]. In fact,
immune and nonimmune cells present on their membrane
specific receptors deputed to recognize PAMPs, such as Toll-
like receptors (TLRs) [14]. Apart from membrane-bound
TLRs, soluble TLRs were also described. These molecules
can be found in body fluids upon bacterial sensing [15–17]
and, acting as decoy receptors for PAMPs, they negatively
regulatemembrane-boundTLR activation in order to prevent
exaggerated innate immune activation [18–20]. Interestingly,
soluble TLRs have been proposed as potential biomarkers for
several inflammatory/infectious conditions, including IBD
[21–26].
Both endothelial cells and platelets possess innate immu-
nity receptors, such as TLR2 and TLR4 [27–29], that, after
being activated by PAMPs, promote cell activation and the
subsequent release of different procoagulative molecules, all
of them triggering the molecular pathways of coagulation.
In the present paper, we evaluated the potential link
between decreased intestinal barrier function and activation
of coagulation in IBD. To this aimwe explored the correlation
between circulating LPS, soluble TLR2 and TLR4 serum
levels, and sensitive markers of activated coagulation (i.e.,
D-Dimer and prothrombin fragment F1 + 2) [30], thus
evaluating the final steps of the coagulatory cascade.
2. Materials and Methods
2.1. Patients. After having read and signed a specific
informed consent, 58 consecutive IBD patients (35 CD and
23 UC) followed up at the Gastroenterology and Gastroin-
testinal EndoscopyUnit of the IRCCS Policlinico SanDonato
and 20 healthy controls were enrolled in the study. Blood was
collected from all IBD patients and all control subjects. All
IBD diagnoses had been confirmed by standardized clinical,
endoscopic, and histologic criteria [31, 32]. Disease activity
was assessed using the Harvey-Bradshaw Index (HBI) for CD
patients [33] and the Mayo scores for UC [34]. Patients with
proctitis were excluded from the study.The demographic and
clinical characteristics of the patients are reported in Table 1.
The study was designed to respect the ethical guidelines of
the Declaration of Helsinki.The Internal Review Board of the
local Ethical Committee approved the study protocol (Ethical
Committee Protocol number # 2025,ASLMilano-2, approved
on June 14, 2007).
2.2. Blood Sampling and Serum and Plasma Collection.
Peripheral blood was collected by venipuncture of an ante-
cubital vein without any blood stasis using sterilized needles
in BD vacutainer SST II Advance for serum collection and in
BD vacutainer with sodium citrate for plasma collection. A
3mL blood tube was used for serum and plasma separation
after centrifugation at 2370 g for 15min at room temperature.
Serum and plasma were stored at −80∘C in 0.5mL aliquots
until the time of assays.
2.3. C Reactive Protein Measurement. C reactive protein
(CRP) levels were measured by a commercially available
immunoturbidimetric assay (Roche Diagnostic, Germany).
2.4. TLR2 and TLR4 Protein Quantification in Serum. The
measurement of TLR2 and TLR4 was performed by means
of commercially available sandwich enzyme immunoassay
(R&D System, USA, and USCN Life Sciences Inc., China,
resp.), following manufacturers’ instructions.
2.5. LPS Quantification. The Endpoint Chromogenic Limu-
lus Amebocyte Lysate (LAL) Test (Lonza) was used as a
quantitative test for LPS, according tomanufacturer’s instruc-
tions. Briefly, serum was diluted 1 : 10 with LAL reagent water
(LRW), heat inactivated in awater bath for 15minutes at 70∘C,
and then diluted 1 : 2 in LRW. The test was performed in a
microplate at 37∘C in heating block. Each sample was tested
in duplicate. Fifty 𝜇L of diluted sample was mixed with 50𝜇L
of the LAL supplied in the test kit and incubated at 37∘C
(±1∘C) for 10 minutes. One hundred 𝜇L of substrate solution
was then mixed with the LAL sample and incubated at 37∘C
(±1∘C) for an additional 6 minutes. The reaction was stopped
with 100 𝜇L acetic acid 25% v/v in water. The absorbance of
the sample was determined spectrophotometrically at 405–
410 nm.
2.6. D-Dimer and F1 + 2 Dosage. D-Dimer HS kit (Instru-
mentation Laboratory, Spain) was used for the quantitative
determination of D-Dimer in human citrated plasma, fol-
lowing manufacturer’s instructions. Briefly, the D-dimer HS
500 latex reagent is a suspension of polystyrene latex particles
of uniform size coated with the F(ab󸀠)
2
fragment of a mon-
oclonal antibody highly specific for the D-Dimer domain
included in fibrin soluble derivatives. Plasma containing D-
Dimer was mixed with the latex reagent and the reaction
buffer, obtaining agglutination directly proportional to theD-
Dimer concentration.
ENzygnost F1 + 2 sandwich ELISA test (Siemens, Ger-
many) was used to measure prothrombin fragment F1 + 2,
according to manufacturer’s instructions.
2.7. Statistical Analysis. Data were analyzed by use of a com-
puterized program (GraphPad Prism, GraphPad Software
Inc., San Diego, CA). Statistical methods employed included
the use of Mann-Whitney Test and Spearman Correlation
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Table 1: Demographic and clinical characteristics of enrolled IBD patients.
Diagnosis CD UC Controls
# of patients 35 23 20
Age (mean ± SD) 40.79 ± 16.68 45.39 ± 15.14 39.79 ± 13.24
Sex (male/female) 16/19 15/8 12/8
Location CD
Ileal (L1) 11 — —
Colonic (L2) 17 — —
Ileocolonic (L3) 7 — —
Upper GI (L4) 0 — —
Extent UC
Left sided colitis — 6 —
Extensive colitis — 17 —
Disease behavior CD
Nonstricturing, nonpenetrating (B1) 21 — —
Stricturing (B2) 8 — —
Penetrating (B3) 1 — —
Perianal disease 5 — —
Previous resective surgery 2 — —
Disease activity indexes
Harvey-Bradshaw Index (mean ± SD) 5.37 ± 4.02 — —
Mayo score (mean ± SD) — 6.96 ± 3.85 —
Folate serum levels (mcg/L) 5.98 ± 2.02 6.56 ± 3.28
Vitamin B12 serum levels (ng/L) 398.4 ± 230.0 330.8 ± 124.5
Test. Data are presented as the median and interquartile
range. The statistical significance was set at 𝑃 < 0.05.
3. Results
3.1. Circulating LPS Is Increased in IBD Patients and Correlates
with TLR2 and TLR4 Serum Concentration in UC. In order
to evaluate the penetration of PAMPs in the blood flow,
as a result of a defective intestinal barrier function in IBD,
we measured circulating LPS in the sera of IBD patients
versus control subjects. LPS levels were more elevated in CD
(0.400 (95% CI 0.333–0.540) EU/mL) and UC (0.430 (95%
CI 0.276–0.677) EU/mL) patients compared with controls
(0.325 (95% CI 0.264–0.411) EU/mL; 𝑃 = 0.044 and 𝑃 =
0.205, resp.) (Figure 1(a)). When performing a subanalysis of
CD patients according to their disease location, as described
by the Montreal classification [35], we detected significantly
increased LPS levels in patients with colonic disease (0.420
(95% CI 0.350–0.620) EU/mL) compared to controls (𝑃 =
0.031) (Figure 1(a)).Then, wemeasured serum concentration
of TLR2, as putative aspecific marker of systemic innate
immune activation. Similarly to LPS, we found more abun-
dant TLR2 in CD (517.21 (95% CI 412.07–890.73) pg/mL)
and UC (447.60 (95% CI 339.90–704.41) pg/mL) sera versus
controls (281.15 (95% CI 122.23–412.05) pg/mL; 𝑃 = 0.002
and 𝑃 = 0.040, resp.) (Figure 1(b)). Interestingly, only
CD patients with colonic or ileocolonic involvement showed
increased TLR2 levels (512.80 (95% CI 436.92–778.27) and
656.72 (95% CI 578.43–1195.55) pg/mL, resp.; 𝑃 = 0.003 and
𝑃 = 0.003, resp.) compared to controls. We next analyzed
the correlation between LPS and TLR2 levels; although we
did not find any correlation between these two variables,
when considering the whole IBD patients (Figure 1(c)) or
CD patients (Figure 1(d)), a significant correlation (𝑟 =
0.495, 𝑃 = 0.016) was observed when we considered UC
patients separated from CD ones (Figure 1(d)). In addition,
subanalysis of CD patients according to disease location did
not reveal any further association (data not shown). We also
evaluated the correlation between serum TLR4 (Figure 2(a)),
that is, the principal innate immune receptor for LPS, and
circulating LPS, and we detected a significant correlation
(𝑟 = 0.421, 𝑃 = 0.001) (Figure 2(b)); interestingly, when
we repeated the analysis dividing patients according to their
disease, we found more robust correlation for UC (𝑟 = 0.512,
𝑃 = 0.008) and CD with colonic involvement (L2 + L3)
(𝑟 = 0.468, 𝑃 = 0.024) than for CD as a whole (𝑟 = 0.332,
𝑃 = 0.054) (Figure 2(c)).
3.2. LPS Levels Correlate with Biochemical but Not Clinical
Activity in IBD Patients, Whereas TLR2 and TLR4 Levels Are
Independent of Disease Activity. In order to evaluate whether
or not circulating LPS, TLR2, and TLR4 were merely markers
of systemic inflammation or disease activity, we analyzed
the correlation between those variables with a biochemical
activity marker, that is, CRP, and two commonly used clinical
activity indexes, such as the Mayo score for UC and the
Harvey-Bradshaw Index for CD. Our analysis was able to
demonstrate only a weak correlation between circulating
LPS and CRP concentrations (𝑟 = 0.295, 𝑃 = 0.035)
(Figure 3).Weobserved no correlation at all when subanalysis
4 Gastroenterology Research and Practice
0.0
0.5
1.0
1.5
2.0
2.5
LP
S 
(E
U
/m
L)
0.0
0.5
1.0
1.5
2.0
2.5
LP
S 
(E
U
/m
L)
CO
N
T
U
C
CD
CO
N
T
CD
 L
1
CD
 L
2
CD
 L
3
P = 0.044 P = 0.031
(a)
0
2000
4000
6000
8000
TL
R2
 (p
g/
m
L)
0
2000
4000
6000
8000
TL
R2
 (p
g/
m
L)
CO
N
T
U
C
CD
CO
N
T
CD
 L
1
CD
 L
2
CD
 L
3
P = 0.002
P = 0.04
P = 0.003
P = 0.003
(b)
0.0 0.5 1.0 1.5 2.0 2.5
0
2000
4000
6000
8000
LPS (EU/mL)
TL
R2
 (p
g/
m
L)
(c)
0.0 0.5 1.0 1.5 2.0 2.5
0
2000
4000
6000
8000
LPS (EU/mL)
TL
R2
 (p
g/
m
L)
0.0 0.5 1.0 1.5 2.0 2.5
0
2000
4000
6000
8000
LPS (EU/mL)
TL
R2
 (p
g/
m
L)
r = 0.495
P = 0.016
(d)
Figure 1: Circulating LPS and TLR2 are increased in IBD and correlate with each other in UC. Concentrations of LPS and TLR2 were
measured in the sera of IBD (both UC and CD) patients and healthy controls (CONT). (a) LPS serum levels in CONT, UC, and CD patients
(left panel) and CD locations according to Montreal classification (right panel). (b) TLR2 serum levels in CONT, UC, and CD patients (left
panel) and CD locations according to Montreal classification (right panel). (c) Correlation between circulating levels of LPS and TLR2 in
IBD patients. (d) Correlation between circulating levels of LPS and TLR2 in UC (left panel) and CD (right panel) patients. Horizontal bars
in (a) and (b) represent median and interquartile range. Statistical analysis was performed by means of Mann-Whitney Test and Spearman
Correlation Test. 𝑃 < 0.05 was considered statistically significant.
for disease and disease location was performed (data not
shown), suggesting that LPS, TLR2, and TLR4 levels are
mostly independent of disease activity. No correlations have
been observed with the clinical indexes (i.e., Mayo score and
Harvey-Bradshaw Index) (Figure 3).
3.3. Concentrations of Circulating LPS Correlate with Plasma
Levels of Markers of Activated Coagulation. We also mea-
sured the plasma concentrations of D-Dimer and prothrom-
bin fragment F1 + 2, which are well known markers of
activated coagulation and are increased in procoagulative
states. LPS levels significantly correlated with both D-Dimer
(𝑟 = 0.422, 𝑃 = 0.001) and F1 + 2 concentrations (𝑟 =
0.440, 𝑃 = 0.0008) (Figure 4); however, no correlation
was found between TLR2 or TLR4 and those coagulation
markers (Figure 4). On the other hand, when we analyzed
only data obtained in UC patients, we not only confirmed
the correlation between LPS and both D-Dimer (𝑟 = 0.467,
𝑃 = 0.028) and F1 + 2 (𝑟 = 0.521, 𝑃 = 0.012), but
also detected good correlations between TLR2 and D-Dimer
(𝑟 = 0.776, 𝑃 < 0.0001), TLR4 and D-Dimer (𝑟 = 0.560,
𝑃 = 0.006), and TLR4 and F1 + 2 (𝑟 = 0.573, 𝑃 = 0.005)
(Figure 5).When all CDpatientswere considered for analysis,
no significant correlation was found; remarkably, when only
patients with colonic disease (L2 and L3) were taken into
account, correlations between D-Dimer and F1 + 2 and LPS
levels were confirmed (𝑟 = 0.435, 𝑃 = 0.042, and 𝑟 = 0.590,
𝑃 = 0.003, resp.) (Figure 6).
4. Discussion
Since 1972, when Shorter et al. postulated that a primary
defect in gut permeability and barrier function may lead
to the onset of persistent inflammation in the gut and to
the development of IBD [36], a growing body of evidence
has demonstrated that the impairment of intestinal barrier
function is a common feature in IBD patients leading to
derangements in both epithelial permeability to gut antigens
and early mucosal innate immune responses, protecting
frommicroorganisms penetration andbacterial translocation
[8, 9]. Interestingly, genetic studies demonstrated a strong
correlation between the carriage of polymorphisms of genes
regulating intestinal epithelial paracellular permeability and
the risk of developing UC [37, 38], whereas being carrier of
innate immunity-related gene polymorphisms increases the
susceptibility to CD [38].
Patients suffering from IBD, and particularly UC [39],
are more prone to incur into thromboembolic events [40],
Gastroenterology Research and Practice 5
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Figure 2: TLR4 serum correlates with circulating LPS in IBD patients. Concentrations of LPS and TLR4 were measured in the sera of IBD
(both UC and CD) patients. (a) TLR4 serum levels in UC and CD patients (left panel) and CD locations according to Montreal classification
(right panel). (b) Correlation between circulating levels of LPS and TLR4 in IBD patients. (c) Correlation between circulating levels of LPS
and TLR4 in UC (left panel), CD (central panel) patients, and CD patients with colonic and ileocolonic involvement (L2 + L3 according to
Montreal classification) (right panel). Horizontal bars in (a) represent median and interquartile range. Statistical analysis was performed by
means of Spearman Correlation Test. 𝑃 < 0.05 was considered statistically significant.
similarly to patients affected by other inflammatory and
immune-related disorders [6]; however, the only presence of
an ongoing inflammatory process does not explain by itself
this phenomenon. In fact, it has been shown that the risk
of thromboembolism is more elevated in IBD than rheuma-
toid arthritis, a disease often characterized by a prominent
systemic inflammation [7], thus suggesting that some gut
specific mechanisms may be involved. Besides deficiencies
of vitamins involved in the proper regulation of coagulatory
homeostasis, such as vitamin B6, vitamin B12, and folic acid
[11–13], the alteration of intestinal barrier function may be a
cofactor promoting a procoagulative state in IBD.
The data presented in this paper strongly support this
novel hypothesis. In fact, in order to assess intestinal perme-
ability to PAMPs and bacterial translocation from the gut, we
measured circulating LPS and found higher concentrations
of this bacterial component in the sera of IBD patients (Fig-
ure 1(a)). Consistent with the data previously presented by
Candia et al. [26], IBD patients also presented higher serum
levels of TLR2, as a sign of innate immune activation (Figures
1(b), 1(c), and 1(d)). Remarkably, serum TLR2 was recently
described to correlate with the presence of prosthetic joint
infection in patients undergoing revision of joint arthroplasty,
because of suspected local infection [23]; thus, circulating
TLR2may be considered amarker of the presence of bacterial
components in the blood flow. Moreover, high levels of
soluble TLR2 were shown in the sera of patients affected by
psoriasis [21] and systemic lupus erythematosus [25], diseases
in which innate immunity plays a major pathogenetic role
[41, 42]. As such, high levels of soluble TLR2 may reflect the
activation of innate inflammatory responses.
LPS levels correlated with the serum concentrations of
TLR4, which is the innate immune receptor deputed to LPS
recognition (Figure 2). This may be a sign of an increased
expression and activation of TLR4, because of LPS binding.
Apart from a very modest correlation between LPS
and CRP levels, LPS, TLR2, and TLR4 concentrations did
not appear to be influenced by biochemical and clinical
disease activity (Figure 3), suggesting that their levels may be
influenced, for the great part, by intestinal permeability.
Both TLR2 and TLR4 are expressed by platelets and
endothelial cells [27–29]; moreover the binding of their
respective ligands causes the procoagulatory activation of
these cell populations. More in detail, TLR2 signaling in
platelets leads to a thromboinflammatory response, through
the activation of phosphoinositide 3-kinase [43], cyclooxy-
genase, and purinergic P2Y1 and P2Y12 receptors [44]
and alpha-granule release [45], whereas LPS-TLR4 binding
enhances classical agonist-induced platelet aggregation [46,
47]. The TLR2 and TLR4 signaling on endothelial cells
6 Gastroenterology Research and Practice
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Figure 3: Circulating LPS correlates with biochemical but not clinical activity in IBD patients. Concentrations of LPS, TLR2, TLR4, and
CRP were measured in the sera of IBD (both UC and CD) patients. Clinical activity of UC and CD was evaluated using Mayo score and
Harvey-Bradshaw Index. (a) Correlation between CRP serum levels and circulating LPS, TLR2, and TLR4 in IBD patients. (b) Correlation
between Mayo score and circulating LPS, TLR2, and TLR4 in UC patients. (c) Correlation between Harvey-Bradshaw Index and circulating
LPS, TLR2, and TLR4 in CD patients. Statistical analysis was performed by means of Spearman Correlation Test. 𝑃 < 0.05 was considered
statistically significant.
strongly activates NF-𝜅B [5, 29], leading to the release of
proinflammatory mediators, which can activate the coagula-
tory cascade. Nonetheless, the pathogenesis of atherosclerotic
plaques ismediated by the presence of activatedmacrophages
within the plaque, which also respond vigorously to TLR
stimulation releasing proinflammatory cytokines [48].
Given themultiplicity of cell types and pathways involved
in the activation of coagulation mediated by TLRs, we
decided tomeasure the activation products of the coagulation
and fibrinolysis, that is, the fibrin degradation product D-
Dimer and prothrombin fragment F1 + 2, as they describe
closely the overall activation of the coagulatory cascade [30].
Remarkably, LPS levels significantly correlated with both
D-Dimer and F1 + 2 (Figure 4), clearly suggesting that
circulating PAMPsmay function as triggers for the activation
of coagulation.
It may be worthy to note that the correlation between
circulating LPS and markers of activated coagulation was
stronger when considering only UC patients (Figures 1(d),
2(c), and 5) and CD patients with colonic or ileocolonic
disease (L2 and L3 according to Montreal classification [35])
(Figure 6).These data suggest that the presence of colonic dis-
ease is the key risk factor for coagulatory unbalance that may
follow bacterial translocation from the gut; indeed, the colon
has to cope with a significantly greater bacterial burden than
the rest of the gastrointestinal tract; as such it is rational that
a break-down of intestinal barrier function in this site might
lead to amore prominent bacterial penetration/translocation.
Moreover, in order to explain the differences we found in
UC versus CD, other issues should be taken into account: CD
patients often display greater signs of systemic inflammation
rather than UC; as such, data coming from CD patients may
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Figure 4: Circulating LPS correlates with markers of activated coagulation in IBD patients. Concentrations of LPS, TLR2, and TLR4 and
levels of D-Dimer and prothrombin fragment F1 + 2 were measured in the sera and plasma, respectively, of IBD patients. (a) Correlation
between D-Dimer plasma levels and serum LPS, TLR2, and TLR4 in IBD patients. (b) Correlation between prothrombin fragment F1+2 and
circulating LPS, TLR2, and TLR4 in IBD patients. Statistical analysis was performed by means of Spearman Correlation Test. 𝑃 < 0.05 was
considered statistically significant.
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Figure 5: Circulating LPS, TLR2, and TLR4 correlate with markers of activated coagulation in UC patients. Concentrations of LPS, TLR2,
and TLR4 and levels of D-Dimer and prothrombin fragment F1 + 2 were measured in the sera and plasma, respectively, of UC patients.
(a) Correlation between D-Dimer plasma levels and serum LPS, TLR2, and TLR4 in UC patients. (b) Correlation between prothrombin
fragment F1 + 2 and circulating LPS, TLR2, and TLR4 in UC patients. Statistical analysis was performed by means of Spearman Correlation
Test. 𝑃 < 0.05 was considered statistically significant.
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Figure 6: Circulating LPS correlates with markers of activated coagulation in CD patients with colonic involvement. Concentrations of LPS
and levels of D-Dimer and prothrombin fragment F1 + 2 were measured in the sera and plasma, respectively, of CD patients. (a) Correlation
between D-Dimer plasma levels and serum LPS in all CD patients (left panel), CD patients with exclusive ileal involvement (L1 according
to Montreal classification) (central panel), and CD patients with colonic involvement (L2 + L3 according to Montreal classification). (b)
Correlation between prothrombin fragment F1 + 2 and circulating LPS in all CD patients (left panel), CD patients with exclusive ileal
involvement (L1 according to Montreal classification) (central panel), and CD patients with colonic involvement (L2 + L3 according to
Montreal classification). Statistical analysis was performed by means of Spearman Correlation Test. 𝑃 < 0.05 was considered statistically
significant.
suffer from the noise resulting from inflammation-driven
activation of coagulation; as an alternative, PAMPs-mediated
coagulatory activation may have a different relevance or
follow different pathways in UC versus CD, also considering
that genetic data suggest different defects in intestinal barrier
function in those two diseases [38].
Taken together, our data support the novel hypothesis
that intestinal barrier defects contribute to the development
of a procoagulatory state in IBD. Our results need to be
confirmed with future studies; in fact, the correlations we
observed in human patients do not demonstrate the bio-
logical importance of the phenomenon we are postulating.
A further limitation of our study is that we are using
very simple markers in order to explore extremely complex
systems. Indeed, experiments on animal models of intestinal
inflammation are warranted in order to provide the final
demonstration of our hypothesis and mechanistically dissect
it and evaluate its real biologic relevance.
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